March 23 (Reuters) - Eupraxia Pharmaceuticals Inc : * EUPRAXIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND 2022 FINANCIAL RESULTS * EUPRAXIA PHARMACEUTICALS INC - BELIEVES ITS CURRENT CASH IS
March 23 (Reuters) - Lucy Scientific Discovery Inc : * LUCY SCIENTIFIC DISCOVERY ANNOUNCES PARTNERSHIP WITH HIGH TIMES® TO DEVELOP AND DISTRIBUTE A NEW LINE OF PSYCHOACTIVE PRODUCTS Source text for
March 23 (Reuters) - Alerts on Aeterna Zentaris's Q4 results have been withdrawn as they were incorrectly published from a Palisade Bio press release, an unrelated company. For correct alerts on
March 23 (Reuters) - Immunoprecise Antibodies Ltd : * IMMUNOPRECISE PRESENTS NOVEL T-CELL ENGAGING BISPECIFIC ANTIBODIES ADDRESSING A UNIQUE ONCOLOGICAL TARGET, TROPOMYOSIN RECEPTOR KINASE B,
March 23 (Reuters) - Knight Therapeutics Inc: * KNIGHT THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2022 RESULTS * FOR FISCAL 2023, EXPECTS TO REPORT $280 TO $300 MILLION IN REVENUE * QTRLY LOSS
March 23 (Reuters) - Charlotte's Web Holdings Inc : * CHARLOTTE'S WEB REPORTS 2022 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS * CHARLOTTE'S WEB HOLDINGS INC Q4 LOSS PER SHARE $0.23 * CHARLOTTE'S
March 22 (Reuters) - FSD Pharma Inc: * FSD PHARMA ANNOUNCES ITS AUSTRALIAN ENTITY RECEIVES APPROVAL TO PROCEED WITH PHASE 1 CLINICAL TRIAL OF LUCID-201, A CANDIDATE FOR THE POTENTIAL TREATMENT OF
March 22 (Reuters) - Medexus Pharmaceuticals Inc : * MEDEXUS ANNOUNCES NEW LICENSE DEAL FOR TOPICAL TERBINAFINE * MEDEXUS PHARMACEUTICALS INC - SECURED CANADIAN RIGHTS TO COMMERCIALIZE TERBINAFINE
21 March 2023 09:21 p.m. All figures in US dollars. Aptose Biosciences Inc is expected to show an increase in its fourth quarter earnings to -11 cents per share according to the mean Refinitiv
* Aptose Biosciences Inc is expected to show no change in quarterly revenue when it reports results on March 23. * * Refinitiv's mean analyst estimate for Aptose Biosciences Inc is for a loss of 11